Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge

Hans Scherübl

doi:10.1055/a-1821-9108

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2023; 61(06): 683-689
DOI: 10.1055/a-1821-9108

Übersicht

Typ-2-Diabetes mellitus und gastrointestinale Krebsvorsorge

Type-2-diabetes and gastrointestinal cancer screening

Hans Scherübl

¹Klinik für Innere Medizin; Gastroenterol., GI Onkol. u. Infektiol., Vivantes Klinikum Am Urban, Berlin, Germany

› Author Affiliations

Abstract

Zusammenfassung

In Deutschland sind mehr als 8 Millionen Menschen diabeteskrank. Patienten mit Typ-2-Diabetes mellitus (T2D) haben ein erhöhtes Risiko für gastrointestinale Adenokarzinome, sie erkranken z.T. früher und weisen i.d.R. ein ungünstigeres, tumorspezifisches 5-Jahres-Überleben auf als Stoffwechselgesunde. Krebs ist nun die Haupttodesursache von Menschen mit T2D. Die chronische Hyperglykämie und die Insulinresistenz können das Wachstum von gastrointestinalen Tumoren begünstigen. So kann T2D Adenokarzinome des Dickdarms, der Bauchspeicheldrüse, der Gallenblase, der Gallengänge, der Leber, des Magens und der Speiseröhre verursachen. Ein gesunder Lebensstil und die Teilnahme an Vorsorgeuntersuchungen sind wichtig und können das tumorbedingte Erkrankungs- und Sterberisiko von T2D-Patienten erheblich verringern.

Abstract

More than 8000000 Germans suffer from diabetes. People with type-2-diabetes (T2D) are at increased risk of gastrointestinal adenocarcinomas. They often develop cancer at younger age and their tumor-specific 5-year-survival is generally shorter. Cancer has become the leading cause of death of T2D-patients. Both chronic hyperglycemia and insulin resistance can stimulate gastrointestinal (GI) tumor growth. T2D can cause colorectal, pancreatic, hepatocellular, biliary and gastric cancer as well as esophageal adenocarcinoma. Both low-risk lifestyle and gastrointestinal cancer screening are effective and reduce GI cancer risk and GI cancer mortality of T2D-patients.

Schlüsselwörter

kolorektales Karzinom - Leberkrebs - Magenkarzinom - Ösophaguskarzinom - Pankreaskarzinom

Keywords

colorectal cancer - hepatocellular carcinoma - gastric cancer - esophageal cancer - pancreatic cancer

Full Text

References

Literatur
1 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 09: 165-173
2 Collier A, Meney C, Hair M. et al. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes patients: A population-based study (The Ayrshire Diabetes Follow-up Cohort study). J Diabetes Investig 2020; 11 (01) 55-61
3 Nakamura J, Kamiya H, Haneda M. et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017; 08 (03) 397-410
4 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle- aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
5 Tsilidis KK, Kasimis JC, Lopez DS. et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015; 350: g7607
6 Chen Y, Wu F, Saito E. et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 2017; 60 (06) 1022-1032
7 Ling S, Brown K, Miksza JK. et al. Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care 2020; 43 (09) 2313-2322
8 Saarela K, Tuomilehto J, Sund R. et al. Cancer incidence among Finnish people with type 2 diabetes during 1989–2014. Eur J Epidemiol 2019; 34 (03) 259-265
9 Bjornsdottir HH, Rawshani A, Rawshani A.. et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci Rep 2020; 10: 17376
10 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 04: e137-e147
11 Ali Khan U, Fallah M, Sundquist K. et al. Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study. PLoS Med 2020; 17: e1003431
12 Lu S, Wang A, Miao S. et al. Association between type 2 diabetes and cancer incidence in China: data in hospitalized patients from 2006 to 2013. Ann Transl Med 2020; 08: 176
13 Li Z, Chen H, Fritz CD. et al. Type 2 Diabetes and Risk of Early-Onset Colorectal Cancer. medRxiv 2021;
14 Mikaeel RR, Symonds EL, Kimber J. et al. Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pac J Clin Oncol 2021; 17: 131-138
15 Wang YG, Wang P, Wang B. et al. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014; 09 (05) e95485
16 Mao Y, Tao M, Jia X. et al. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Sci Rep 2015; 05: 17102
17 Sheng L, Peng H, Pan Y. et al. Evaluating the effect of diabetes on the prognosis of gastric cancer using a propensity score matching method. J Gastrointest Oncol 2020; 11 (05) 999-1008
18 Petrelli F, Ghidini M, Rausa E. et al. Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. Can J Diabetes 2021; 45 (02) 186-197
19 Roderburg C, Loosen SH, Hoyer L. et al. Prevalence of diabetes mellitus among 80,193 gastrointestinal cancer patients in five European and three Asian countries. J Cancer Res Clin Oncol 2021;
20 Ose DJ, Viskochil R, Holowatyj AN. et al. Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study. J Natl Compr Canc Netw 2021; 19 (06) 709-718
21 Wagner C, Cadar D, Hackett RA. et al. Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. J Med Screen 2020; 27: 25-30
22 Bhatia D, Lega IC, Wu W. et al. Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis. Diabetologia 2020; 63 (01) 34-48
23 Chuck KW, Hwang M, Choi KS. et al. Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007–2009. Epidemiol Health 2017; 39: e2017036
24 Valent F, Gobbato M, Franzo A. et al. Diabetes mellitus and colorectal cancer screening in the population of the Italian region Friuli Venezia Giulia. Epidem Biostati Public Health 2017; 14
25 Wu Y, Li Y, Giovannucci E. Potenzial Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology 2021; 161 (06) 1830-1841.e8
26 Li H, Boakye D, Chen X. et al. Associations of body mass index at different ages with early-onset colorectal cancer. Gastroenterology 2022;
27 GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 04: 934-947
28 Baecker A, Liu X, La Vecchia C. et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018; 27: 205-212
29 Vuik F, Nieuwenburg S, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
30 Scherübl H. Übermäßiges Körpergewicht und Krebsrisiko. Dtsch Med Wochenschr 2020; 145 (14) 1006-1014
31 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021;
32 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2021; dc211335
33 Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer 2020; 20: 629-644
34 https://www.nfcr.org/blog/understanding-the-link-between-sugar-and-cancer-2021/
35 Lee SC, Chan JC. Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl) 2015; 128: 1543-1548
36 Chen CL, Yang HI, Yang WS. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135 (01) 111-121
37 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806
38 Gu J, Yan S, Wang B. et al. Type 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev 2016; 32 (01) 63-72
39 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113 (10) 1494-1505
40 Lai HC, Chang SN, Lin CC. et al. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol 2013; 48 (07) 856-865
41 Lee BS, Park EC, Park SW. et al. Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea. World J Gastroenterol 2015; 21 (02) 502-510
42 Blackford AL, Canto MI, Klein AP. et al. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst 2020; 112 (11) 1162-1169
43 Yuan C, Babic A, Khalaf N. et al. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol 2020; 06 (10) e202948
44 Duconseil P, Adham M, Sauvanet A. et al. Fukuoka-Negative Branch-Duct IPMNs: When to Worry? A Study from the French Surgical Association (AFC). Ann Surg Oncol 2018; 25: 1017-1025
45 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
46 Holmberg D, Santoni G, von Euler-Chelpin MC. et al. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. Gastroenterology 2021;
47 Scherübl H, Cataldegirmen G, Eick J. et al. Field cancerization of the upper aerodigestive tract: Screening for second primary esophageal cancers in cancer survivors. EMJ Oncol 2015; 03: 21-28
48 Herrera-Pariente C, Montori S, Llach J. et al. Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines 2021; 09: 1448
49 Cardoso R, Zhu A, Guo F. et al. Inzidenz und Mortalität proximaler und distaler kolorektaler Karzinome in Deutschland – Trends in der Ära der Vorsorgekoloskopie. Dtsch Arztebl Int 2021; 118: 281-287
50 Davidson KW, Barry MJ, Mangione CM. US Preventive Services Task Force. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19) 1965-1977